NKX101

DB18131InvestigationalCell transplant therapies

NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.

Also known as
a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15)
Code names
NKX-101

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of NKX101, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In